Drug Profile
Research programme: eye disorders therapy - Bausch & Lomb/Galapagos
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Galapagos NV
- Developer Bausch & Lomb; Galapagos NV
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Eye-disorders in USA (Ophthalmic)
- 05 Aug 2013 Bausch & Lomb has been acquired by Valeant Pharmaceuticals International
- 10 Apr 2008 Preclinical trials in Eye disorders in USA (Parenteral)